Immune CEO Announces New Operational Leadership Team
April 02 2014 - 2:30AM
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced
today the addition of two new senior members to its management
team.
Elliot Goldstein, MD, joins as Chief Medical Officer. Dr.
Goldstein brings a unique track record in the clinical,
regulatory and commercial development of new
pharmaceuticals. Dr. Goldstein began his career
with Sandoz Pharmaceuticals (now Novartis), a fourteen-year
period on drug development in France, Basel, Switzerland Global
Headquarters, and including as Head of Clinical R&D in the
United States. He subsequently held positions as SVP of
Strategic Product Development at SmithKline Beecham (now GSK),
CEO of British Biotech (Oxford, UK), Chief Operating Officer
and Chief Medical Officer of Maxygen, and President and CMO of
a startup biotech devoted to development of biosimilar monoclonal
antibodies. Dr. Goldstein holds an M.D. from the
University Aix-Marseille II, Marseille, France, and a B.Sc. from
McGill University, Montreal.
Eugene Williams joins as Chief Operating Officer. Mr. Williams
is a former SVP at Genzyme, with senior roles integrating
commercialization, drug development, and deal making. He is also an
entrepreneur, as the founder and director of Adheris, which became
the largest company in the patient adherence area. He was
previously a strategy consultant at Bain and Corporate Decisions
Inc. (a Bain Spin off, now part of Oliver Wyman), where he was
co-Head of Healthcare and spent extensive time on speeding and
improving the drug development process and on commercialization
strategies. Mr. Williams was most recently the CEO of Dart
Therapeutics, an Orphan Disease drug development company. Mr.
Williams holds a B.A. from Harvard University and an M.B.A. from
Harvard Business School.
"We are very happy to welcome Dr. Elliot Goldstein and Mr.
Eugene Williams to our senior management team," said Immune
Pharmaceuticals' CEO, Dr. Daniel Teper. "Following on our
successful fund raising in March of this year, we are building a
strong management team with the experience and vision to capitalize
on our leading assets in the field of personalized medicine. Both
Elliot and Eugene have a proven track record as innovators, and as
senior leaders in very successful pharma and biotech companies.
They bring significant experience in the disease areas which we
have prioritized for our lead assets - rare diseases, autoimmune
diseases, and oncology."
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. applies a personalized approach to
treatment, developing novel, highly targeted antibody therapeutics
to improve the lives of patients with inflammatory diseases and
cancer. The Company's lead product candidate, bertilimumab, is
in clinical development for moderate to severe
ulcerative colitis and Crohn's Disease as well as bullous
pemphigoid, an orphan auto-immune dermatological condition, Immune
licensed worldwide rights for systemic indications of bertilimumab
from iCo Therapeutics (TSX-V:ICO) (OTCQX:ICOTF) in June 2011, while
iCo retained rights to all ophthalmic indications. iCo originally
licensed the exclusive world-wide rights to bertilimumab in 2006
from MedImmune, the Global Research and Development Arm of
AstraZeneca. Immune's pipeline also includes NanomAbs®,
antibody nanoparticle conjugates, for the targeted delivery of
chemotherapeutics and Amiket™, a Neuropathic Pain drug candidate
ready for Phase III. Amiket has received Fast Track designation for
chemotherapy induced neuropathic pain and Orphan Drug Designation
for Post Herpetic Neuralgia.
For more information, visit Immune's website at
www.immunepharmaceuticals.com, the content of which is not a part
of this press release.
Erik Penser Bankaktiebolag is engaged as Immune's Certified
Adviser on NASDAQ OMX First North Premier.
Forward-Looking Statements
This news release and any oral statements made with respect to
the information contained in this news release contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. You are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of
those words or other comparable words to be uncertain and
forward-looking. Such forward-looking statements include
statements that express plans, anticipation, intent, contingency,
goals, targets, future development and are otherwise not statements
of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause
actual results or developments to differ materially include, but
not limited to: the risks associated with the adequacy of our
existing cash resources and our ability to continue as a going
concern; the risks associated with our ability to continue to meet
our obligations under our existing debt agreements; the risk that
we will not be able to find a partner to help conduct the Phase III
trials for AmiKet™ on attractive terms, a timely basis or at all;
the risk that we will not obtain approval to market and
commercialize any of our product candidates; the risks associated
with dependence upon key personnel; the risks associated with
reliance on collaborative partners and others for further clinical
trials, development, manufacturing and commercialization of our
product candidates; the cost, delays and uncertainties associated
with our scientific research, product development, clinical trials
and regulatory approval process; our history of operating losses
since our inception; the highly competitive nature of our business;
risks associated with litigation; risks associated with our ability
to protect our intellectual property; risks associate with our
ability to raise additional funds; and our liquidity. These factors
and other material risks are more fully discussed in our periodic
reports, including our reports on Forms 8-K, 10-Q and 10-K and
other filings with the U.S. Securities and Exchange Commission. You
are urged to carefully review and consider the disclosures found in
our filings which are available at www.sec.gov or at
www.immunepharmaceuticals.com. You are cautioned not to place undue
reliance on any forward-looking statements, any of which could turn
out to be wrong due to inaccurate assumptions, unknown risks or
uncertainties or other risk factors. We expressly disclaim any
obligation to publicly update any forward-looking statements
contained herein, whether as a result of new information, future
events or otherwise, except as required by law.
CONTACT: Immune Pharmaceuticals Inc.:
708 Third Avenue, Suite 210
New York, NY 10017
Anna Baran, Director of Investor Relations
and Corporate Communications
Tel: (646) 937-1941
anna.baran@immunepharma.com
Immune Pharmaceuticals Ltd.:
11C Galgale HaPlada
Herzliya-Pituach, Israel 46733
International Coal G (NYSE:ICO)
Historical Stock Chart
From Jul 2024 to Aug 2024
International Coal G (NYSE:ICO)
Historical Stock Chart
From Aug 2023 to Aug 2024